VolitionRX Ltd VNRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx Participates in Launch of DETECSEPS Program in France
Trading Information
- Previous Close Price
- $0.18
- Day Range
- $0.16–0.18
- 52-Week Range
- $0.16–7.73
- Bid/Ask
- $0.16 / $0.17
- Shares Outstanding
- 36.08M
- Market Cap
- $5.94M
- Volume/Avg
- 809,177 / 9M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 75
- Website
- https://www.volition.com
Valuation
Metric | VNRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.54 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VNRX |
|---|---|
Quick Ratio | 0.26 |
Current Ratio | 0.33 |
Interest Coverage | −6.40 |
Quick Ratio
VNRX
Profitability
Metric | VNRX |
|---|---|
Return on Assets (Normalized) | −266.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VNRX
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|%N!!p?$ | LOCK|@gW< | $181B | |||
| Medtronic PLC MDT | LOCK|gY$mdX> | LOCK|c#F? | $129B | |||
| Stryker Corp SYK | LOCK|!nf%B%k | LOCK|^@z | $121B | |||
| Boston Scientific Corp BSX | LOCK|#>#scDJ | LOCK|?%m! | $63B | |||
| Edwards Lifesciences Corp EW | LOCK|>kcDtxy< | LOCK|dgFl^ | $61B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|@w<%XQX | LOCK|@m | $38B | |||
| DexCom Inc DXCM | LOCK|BzYZ#<D | LOCK|@CHv | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|!% | LOCK|%z | $29B | |||
| Steris PLC STE | LOCK|^t>^LF! | LOCK|^$t^ | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|S!sm<MHW | LOCK|#WL | $20B |